论文部分内容阅读
目的探讨生发中心型(GCB)与非生发中心型(non-GCB)弥漫大B细胞淋巴瘤临床病理因素及其与预后关系。方法 98例经组织学和免疫组化确诊的弥漫大B细胞淋巴瘤患者,按照Hans免疫分型,GCB型21例(A组),non-GCB型77例(B组),比较两组生存率,分析影响预后的相关因素。结果 A组生存率高于B组(P<0.05);多因素分析显示,两组乳酸脱氢酶(LDH)水平、国际预后指数(IPI)比较差异有统计学意义(P<0.05),LDH、IPI为弥漫大B细胞淋巴瘤的独立预后因素。结论在弥漫大B细胞淋巴瘤中,non-GCB型更为常见,LDH、IPI评分是影响non-GCB型预后的主要因素,应根据患者实际情况选择合适的治疗方案。
Objective To investigate the clinicopathological factors of GCB and non-GCB diffuse large B-cell lymphoma and its relationship with prognosis. Methods A total of 98 patients with diffuse large B-cell lymphoma confirmed by histology and immunohistochemistry were enrolled in this study. According to Hans immunophenotyping, 21 cases of GCB (group A) and 77 cases of non-GCB (group B) Rate, analyze the factors that affect the prognosis. Results The survival rate in group A was higher than that in group B (P <0.05). Multivariate analysis showed that there were significant differences in LDH and IPI (P <0.05), LDH , IPI is an independent prognostic factor for diffuse large B cell lymphoma. Conclusion In diffuse large B cell lymphoma, non-GCB type is more common. LDH and IPI score are the main factors affecting the prognosis of non-GCB type. According to the actual situation of patients, choose the appropriate treatment.